The Cystic Fibrosis (CF) gene is associated with abnormal production and function of the cystic fibrosis transmembrane conductance regulator (CFTR). Despite the widespread expression of CFTR in the brain, neurological complications and malformations of the central nervous system (CNS) are rare. We report two cases of Chiari malformations in adults with CF. Methods: Case records were reviewed. Diagnoses were confirmed by brain MRI scan and neurological assessment. Results: Since 2006, 440 patients ( 17 years) have been followed up in the adult unit. Two patients were diagnosed as having Chiari Type 1 malformation. The first case involved a 26 years old female who presented with secondary amenorrhea due to hypogonadotrophic hypogonadism. Brain MRI demonstrated Chiari type I malformation with hydrocephalus requiring a third ventriculostomy and decompression of foramen magnum. The second patient was a 23 year old male who presented with type II respiratory failure and persistent headache which failed to respond to non invasive ventilation. Brain MRI confirmed Chiari I malformation without evidence of hydrocephalus. Conclusion: Chiari type I malformation is characterized by herniation of the cerebellar tonsils through the foramen magnum and can be either asymptomatic or present with a wide spectrum of neurological symptoms. Although rare (1:1000 births), Chiari type I malformation may be more frequent in patients with CF [1]. The diagnosis should be considering in patients presenting with neurological symptoms.
First Pseudomonas aeruginosa (PSA) colonization of the presently 8-year-old male patient with CF was diagnosed by a routine deep throat swab. Subsequently both, the upper and lower airways (UAW/LAW) were sampled monthly by throat swabs/sputum collection, and nasal lavage, according to the Jena CF-centers' standard for intermittent colonization. The boy's father meticulously documented all therapies and culture results. Initial attempts to eradicate PSA following current German guidelines, with oral ciprofloxacin, inhaled colistin and tobramycin, as well as three cycles of IV ceftazidime and tobramycin failed. After the first positive nasal sample, vibrating nasal inhalation of nebulized colistin (Pari Sinus) was added to the regimen. After 9 positive cultures of PSA from the LAW and 3 from the UAW, we changed to an offlabel regimen consisting of inhaled aztreonam alternating monthly with tobramycin (given simultaneously for UAW and LAW, and IV antibiotics every 3 months, and oral azithromycin Results: RLV increased during all ACT from baseline and was significant for MI:E and NIV (p < 0.05). NIV breath profiles suggested limitation of expiratory flow in comparison to the exsufflation breath of MI:E and IPPB breaths, where an expiratory flow bias was apparent. Expiratory flow bias is essential for effective ACT, preventing embedding of mucus. MI:E was reported as most effective ACT by the patient, with VAS for ease of clearance reducing from 6 to 3. Conclusion: Lung recruitment occurred with all ACT. NIV may limit expiratory flow and sputum clearance. IPPB and MI:E may facilitate sputum clearance due to expiratory flow bias. Patient-reported VAS for ease of sputum clearance favored MI:E. This is a single case study report; further research may be of benefit to further investigate the potential use of MI:E in CF.
